Alzheimer's Drug Discovery Foundation 2018

The Alzheimer's Drug Discovery Foundation's 19th Annual Conference was held in Jersey City, New Jersey, from September 17 to September 18, 2018. It brought together academic and industry scientists intent on accelerating the development of innovative treatments for Alzheimer's disease and related dementias.
Lanctôt advised ruling out any possible underlying medical conditions that could be causing it, including pain, as well as starting with any non-pharmacologic interventions.
The Carl F. Asseff Professor of Ophthalmology and the Director of the Visual Sciences Research Center at Case Western Reserve University spoke about the beginnings of her work with efavirenz.
The Jim Turner Chair in Cognitive Disorders at the Vanderbilt University School of Medicine shared his feelings on the early phase treatments.
Fillit spoke about remaining need for additional biomarkers in Alzheimer, and what has been developed in recent years.
The psychiatry and pharmacology professor at the University of Toronto and senior scientist at Sunnybrook Research Institute spoke about the use of cannabinoids to treat agitation in Alzheimer.
The Carl F. Asseff Professor of Ophthalmology and the Director of the Visual Sciences Research Center at Case Western Reserve University further discussed the trial of efavirenz in AD.
For the associate professor of neurology, learning, listening, and collaborating are the keys to improving the field of care.
The Jim Turner Chair in Cognitive Disorders at the Vanderbilt University School of Medicine explained more about the molecule and the subsequent trial of it.
With a heavy focus on the need for new treatments in Alzheimer, there remains a need to ensure patients are cared for first and foremost.
Could the introduction of gene therapies into the Alzheimer space be the beginning of a new era of treatment?
The associate professor of neurology at Mayo Clinic spoke about targeting mitochondria to treat neurologic disorders.
The ADDF's founding executive director and chief scientific officer spoke about the gains in clinical trials in the last 5 years.
The chairman of the Department of Genetic Medicine at Weill Cornell Medicine shared his experience with the therapy and its potential in the space.

About the Alzheimer’s Drug Discovery Foundation 19th Annual Conference:

The Alzheimer's Drug Discovery Foundation's 19th Annual Conference brings together academic and industry scientists intent on accelerating the development of innovative treatments for Alzheimer's disease and related dementias. NeurologyLive offers the most up-to-date information regarding existing Alzheimer’s treatment options, as well as data from clinical trials evaluating new and emerging therapies, to those unable to travel to network with the ADDF in Jersey City.
 
This Conference Coverage page at NeurologyLive is a full-service resource center for the latest from ADDF 2018, including key developments from research that may potentially lead to a better understanding of Alzheimer’s disease causes, methods of early diagnosis, symptom management, and prevention. It serves as a hub of information and news from the conference and includes focal coverage right from the floor.
 
For related content, check out NeurologyLive’s Alzheimer’s Disease and dementia Condition Center page.